News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
250,294 Results
Type
Article (19922)
Company Profile (120)
Press Release (230252)
Section
Business (77766)
Career Advice (924)
Deals (15512)
Drug Delivery (68)
Drug Development (23890)
Employer Resources (137)
FDA (4348)
Job Trends (7009)
News (122365)
Policy (9328)
Tag
Academia (1527)
Alliances (21229)
Alzheimer's disease (572)
Antibody-drug conjugate (ADC) (48)
Approvals (4319)
Artificial intelligence (74)
Bankruptcy (119)
Best Places to Work (5761)
Biosimilars (44)
Biotechnology (75)
Breast cancer (44)
Cancer (427)
Career advice (817)
Cell therapy (101)
Clinical research (18161)
Collaboration (211)
Compensation (44)
COVID-19 (1000)
C-suite (58)
Data (450)
Diabetes (54)
Diagnostics (2739)
Earnings (20030)
Employer resources (117)
Events (36820)
Executive appointments (179)
FDA (4524)
Funding (191)
Gene therapy (73)
GLP-1 (292)
Government (1439)
Healthcare (6485)
Infectious disease (1040)
Inflammatory bowel disease (50)
Interviews (134)
IPO (7575)
Job creations (1441)
Job search strategy (715)
Layoffs (148)
Legal (1943)
Lung cancer (80)
Manufacturing (87)
Medical device (4066)
Medtech (4070)
Mergers & acquisitions (8072)
Metabolic disorders (170)
Neuroscience (702)
NextGen Class of 2024 (2766)
Non-profit (1775)
Northern California (587)
Obesity (110)
Opinion (89)
People (29753)
Phase I (5469)
Phase II (7755)
Phase III (6824)
Pipeline (159)
Postmarket research (677)
Preclinical (2848)
Press Release (61)
Radiopharmaceuticals (90)
Rare diseases (91)
Real estate (2841)
Recruiting (53)
Regulatory (6373)
Research institute (1339)
Resumes & cover letters (116)
Southern California (462)
Startups (2215)
United States (5395)
Vaccines (180)
Weight loss (84)
Date
Today (63)
Last 7 days (293)
Last 30 days (1421)
Last 365 days (15188)
2024 (13863)
2023 (17168)
2022 (20564)
2021 (23479)
2020 (22000)
2019 (18808)
2018 (13892)
2017 (13203)
2016 (12492)
2015 (14257)
2014 (10280)
2013 (8665)
2012 (9211)
2011 (9290)
2010 (8645)
Location
Africa (339)
Arizona (66)
Asia (14080)
Australia (2256)
California (1274)
Canada (467)
China (86)
Colorado (62)
Connecticut (54)
Europe (32032)
Florida (186)
Georgia (47)
Illinois (125)
Indiana (103)
Maryland (179)
Massachusetts (994)
Michigan (106)
Minnesota (105)
New Jersey (434)
New York (472)
North Carolina (342)
Northern California (587)
Ohio (66)
Pennsylvania (241)
South America (440)
Southern California (462)
Texas (205)
Washington State (114)
250,294 Results for "grace science llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Grace Science, LLC Selected by FDA to Participate in the START Pilot Program for GS-100 Gene Therapy for NGLY1 Deficiency and Announcement of the Successful Treatment of the 2nd Patient
Grace Science, LLC announced today that the IND for GS-100, an AAV9 gene therapy for NGLY1 Deficiency, was accepted into the FDA’s Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.
June 3, 2024
·
3 min read
Drug Development
Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency
Grace Science, LLC announced today that the first patient was dosed in an open-label Phase 1/2/3 clinical trial of GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency.
March 5, 2024
·
2 min read
Business
Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I/II/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency
Andelyn Biosciences has partnered with Grace Science, LLC, to tech transfer and manufacture GS-100, a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.
March 25, 2024
·
3 min read
Press Releases
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
October 28, 2024
·
8 min read
Press Releases
Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
November 13, 2024
·
13 min read
Press Releases
Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024
October 30, 2024
·
10 min read
Drug Development
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics Incorporated today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome).
June 3, 2024
·
3 min read
Drug Development
Grace Science Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Phase 1/2/3 Trial for the Treatment of NGLY1 Deficiency with GS-100, an AAV9 NGLY1 Gene Therapy
Grace Science, LLC announced today that it has received FDA clearance of its Investigational New Drug (IND) application for GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency.
November 7, 2023
·
2 min read
Drug Development
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met its primary endpoint.
May 28, 2024
·
4 min read
Drug Development
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etiologies of endogenous Cushing’s syndrome (hypercortisolism).
April 22, 2024
·
7 min read
1 of 25,030
Next
